Tipanat (Trifluridine + Tipiracil) 20 mg / 8.19 mg, 20 tablets: profile, composition and research

Reference page for Tipanat (Trifluridine + Tipiracil) 20 mg / 8.19 mg, 20 tablets. Active substance: Трифлуридин + типирацил / Trifluridine + Tipiracil.

Key facts

What trifluridine and tipiracil are

Tipanat is an antineoplastic medicine whose tablet combines two substances: trifluridine and tipiracil. They work as a pair, and either one alone would not produce the intended result.

Trifluridine is an analogue of thymidine, the nucleoside a cell uses to build DNA. Tipiracil does not act on the tumour by itself: its role is to protect trifluridine from being broken down too quickly in the body. Together they keep the active substance at a usable level in the blood.

The medicine is taken orally as tablets. That sets it apart from many antineoplastic drugs, which are given intravenously.

How it works

Trifluridine

Once inside a cell, trifluridine is inserted into the DNA chain in place of a normal building block. DNA carrying such a substitution cannot be copied properly, and the division of the tumour cell is disrupted.

Tipiracil

Tipiracil blocks the enzyme thymidine phosphorylase, which degrades trifluridine. Without that protection, trifluridine would fall apart before reaching tumour cells.

The combined effect

The combination is designed so the active substance stays in the body longer and has time to act. Tumour cells divide quickly, which makes them more sensitive to this kind of interference than most healthy tissue.

Approved uses

The prescribing information lists two main directions. The first is metastatic colorectal cancer, that is a tumour of the colon or rectum that has spread to other organs. The second is metastatic gastric cancer, including tumours of the gastroesophageal junction.

In both cases the medicine is used in adults once other treatment options have already been tried. It is not a first-line therapy but one of the later stages: this is a condition of its registration, not a suggestion for self-selection.

Choosing the treatment, its duration and the monitoring of tolerability is the job of an oncologist. The medicine affects blood formation, so blood counts are checked during treatment.

Published research

Primary sources, verified against PubMed:

• Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer, PubMed 36455504 (ESMO Open, 2022).
• Trifluridine/tipiracil in the treatment of gastric cancer, PubMed 35081748 (Future Oncol, 2022).
• The Danish randomized trial of trifluridine-tipiracil and bevacizumab in metastatic colorectal cancer: final survival and post hoc neutropenia analyses, PubMed 42583256 (ESMO Gastrointest Oncol, 2026).

Listed for reference. Publication of a study is not a claim about this particular product.

Precautions

• This is a prescription medicine and is used only under the supervision of an oncologist.
• Treatment affects the blood: neutrophil, platelet and red-cell counts may fall. Monitoring tests are ordered by a physician.
• The medicine is not used during pregnancy or breastfeeding.
• Liver or kidney impairment, as well as bone-marrow conditions, require separate assessment by a doctor.
• Tell your doctor about every other medicine you take: interactions are possible.
• Signs of infection or unusual weakness during treatment should be reported to a doctor without delay.

Frequently asked